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Abstract We verified the hypothesis that changes in the
endogenous GM1 ganglioside density in the environment of
TrkB, receptor of brain-derived neurotrophic factor, can affect
receptor activity, and focused on rat cerebellar granule cells
expressing both GM1 and TrkB. Changes of the amount of GM1
associated to immunoprecipitated TrkB and of receptor tyrosine
phosphorylation were evaluated after treatment with phorbol-12-
myristate-13-acetate (1 WM, 7 min), reported to affect the
plasma membrane distribution of endogenous gangliosides in the
same cells. After treatment, the amount of GM1 associated to
receptor and TrkB phosphorylation decreased by about 40%.
The amount of associated GM1 decreased by about 33% also
after concomitant treatment with phorbol ester and brain-derived
neurotrophic factor, but in this case the neurotrophin was unable
to enhance receptor tyrosine phosphorylation. These results for
the first time suggest that changes in the amount of endogenous
GM1 in the environment of TrkB can modulate receptor activity,
and offer new clues for a better understanding of physiological
and pathological events of the nervous system.
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1. Introduction
Neurotrophins (NT), a family of polypeptides promoting
the di¡erentiation and survival of both central and peripheral
neurons, include molecules such as the brain-derived neuro-
trophic factor (BDNF), nerve growth factor (NGF), neuro-
trophin-3, and neurotrophin-4/5. Neurotrophins initiate signal
transduction in responsive cells by ligand-induced dimeriza-
tion and activation of a receptor tyrosine kinase of the tyro-
sine kinase (Trk) family [1]. The existence of a relationship
between gangliosides and NT receptors has been documented
(for a review on the argument see [2]). The knowledge that
gangliosides enhance NT action [2], that GM1 ganglioside
interacts with the NGF receptor [3,4], and that endogenous
GM1 co-localizes with the BDNF receptor in neuronal mem-
brane domains [5], suggests the importance of these interac-
tions in physiological functions and pathological events of the
nervous system, even though the underlying mechanisms have
not been completely clari¢ed. Although it is known that exo-
genously administered gangliosides can a¡ect Trk activity [3],
the in£uence of endogenous gangliosides, and in particular of
changes in their local concentration in the receptor environ-
ment, is unknown. We decided to investigate this issue and,
starting from the hypothesis of a possible correlation between
GM1 ganglioside and TrkB, the BDNF receptor, we carried
out the investigation using rat cerebellar granule cells, known
to express both the glycolipid and the protein [6,7]. Our ap-
proach consisted of monitoring changes of the amount of
endogenous GM1 associated with TrkB and, on the other
side, of the receptor activity, consequent to a stimulus able
to modify the distribution of endogenous gangliosides at the
level of the plasma membrane. This modi¢cation was brought
about by the addition of a phorbol ester, a procedure that we
recently set up using the same cellular system [7].
2. Materials and methods
2.1. Materials
TLC plates and common chemicals were from Merck (Darmstadt,
Germany). Basal modi¢ed Eagle’s medium, fetal calf serum (FCS;
heat-inactivated before use), poly-L-lysine, 1-K-D-arabinofuranosylcy-
tosine, gentamycin, Triton X-100, phorbol-12-myristate-13 acetate
(PMA) and crystalline bovine serum albumin were obtained from
Sigma (St. Louis, MO, USA). BDNF was from Alexis (Laufel¢ngen,
Switzerland). Standard GM1 ganglioside was extracted and puri¢ed
from calf brain [8]. Secondary antibodies and enhanced chemilumi-
nescence (ECL) detection kit were from Amersham International
(Amersham, UK). Horseradish peroxidase (HRP)-conjugated cholera
toxin B subunit (CTB) was from List Biological (Vandell Way, CA,
USA). The anti-TrkB antibody used in this study for immunopreci-
pitation experiments was obtained from albino rabbits immunized
with an HPLC-puri¢ed synthetic peptide (TrkB-peptide) representing
a 14-amino acid residue derived from the C-terminus of TrkB protein
[3]. This antibody can cross-react weakly with TrkA and TrkC pro-
tein. For this reason, for immunoblotting experiments we used an
anti-TrkB antibody (794) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), which is more speci¢c than ours towards TrkB,
even if its titer is weaker. Anti-phosphotyrosine (TyrP) antibodies
(4G10) were from Upstate Biotechnology (Lake Placid, NY, USA).
2.2. Cell cultures and cell treatment
Cerebellar granule cells, obtained from 8-day-old Sprague-Dawley
rats (Charles River), were prepared and cultured according to [9].
Glial proliferation was prevented by adding cytosine arabinofurano-
side (¢nal concentration, 10 WM) 18^20 h after plating. Cells were
grown on 100-mm plastic dishes coated with poly-L-lysine and used
for the experiments after 6 days in vitro. Cells were treated with PMA
according to a procedure able to exert a change of ganglioside distri-
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bution in the plasma membrane of cerebellar granule cells [7], with
minor modi¢cations. Brie£y, the cells were preincubated in serum-free
medium for 1 h at 37‡C and then treated for 7 min with PMA (1 WM),
or with BDNF (100 ng/ml), or both. After treatment, the cells were
harvested and submitted to immunoprecipitation, as described below.
2.3. Assessment of the total content of GM1 in cultured cells
The total GM1 ganglioside content was assessed in control and in
PMA-treated cells as described [7]. Brie£y, gangliosides were extracted
and puri¢ed from a pool of cells prepared from ¢ve 60-mm diameter
dishes. The fractionation and quanti¢cation of GM1 was accom-
plished by analytical HPLC using a photodiode-array detector and
peak integration, as described [7,10].
2.4. Immunoprecipitation
Immunoprecipitation was performed according to [3], the only dif-
ference being that 1% Triton X-100, instead of Nonidet P-40, was
used in the lysis bu¡er. Cell lysates were normalized for the protein
content and immunoprecipitated with an anti-TrkB antibody, as de-
scribed [3].
2.5. Assessment of the amount of GM1 ganglioside co-precipitated
with TrkB
After immunoprecipitation with anti-TrkB antibodies, an aliquot of
the immunoprecipitate was submitted to lipid extraction [11]. The
extract was submitted to TLC (solvent system chloroform/methanol/
CaCl2, 0.2%, 50:42:11 by vol.). The identi¢cation of GM1 was ac-
complished using the immunostaining with HRP-conjugated CTB,
already described [3], followed by ECL detection. Quanti¢cation of
GM1 was accomplished by comparison with known amounts of
standard ganglioside.
2.6. Assessment of tyrosine phosphorylation of TrkB
An aliquot of the immunoprecipitate obtained with anti-TrkB anti-
bodies from cell lysates, was submitted to electrophoresis on sodium
dodecylsulfate (SDS)/8% polyacrylamide gels, transferred to poly-
vinylidene di£uoride membranes and probed with anti-TyrP antibody.
Detection was performed according to the manufacturers’ directions
(ECL, Amersham). Manufacturers’ speci¢ed protocols were also used
to strip anti-TyrP antibody from the blots and to reprobe the mem-
branes with antibodies against TrkB. In order to quantitatively eval-
uate the e¡ects exerted by cell treatments, the tyrosine phosphoryla-
tion of each sample was normalized for the TrkB content of the same
sample. For this purpose, ¢lms of the ECL-visualized immunoblots
were quanti¢ed by densitometry. Then, the digitized band in the blot
obtained with anti-TyrP was divided by the digitized band of the same
sample in the blot obtained with anti-TrkB.
3. Results
3.1. Amount of GM1 ganglioside co-precipitated with
TrkB receptor
The amount of GM1 co-precipitated with TrkB, from ly-
sates of control cells, was 12 þ 1 pmol/mg cell proteins (Fig. 1).
We could detect neither TrkB protein nor GM1 in the immu-
noprecipitate when the immunoprecipitation was carried out
in the presence of TrkB-immunogen, added at the ¢nal con-
centration of 1 mg/ml. Using pre-immune serum instead of
anti-TrkB antibody and submitting the cells to the immuno-
precipitation procedure, the amounts of GM1 and TrkB re-
covered in the immunoprecipitate were below the detection
limit of the technique used.
The assessment of GM1 in the immunoprecipitate was per-
formed after cell treatment with PMA. In this case the
amount of GM1 co-precipitated with the receptor was lower
(7.2 þ 0.9 pmol/mg cell proteins) than in control cells. A lower
amount of GM1 associated with the receptor (8 þ 1 pmol/mg
cell proteins) was also detected in cells after treatment with
PMA and BDNF.
As a control, the possible e¡ect of the PMA treatment on
the total GM1 content of cells was also evaluated. The results
showed that, under the experimental conditions adopted, the
content of GM1 (data not shown) was not a¡ected by the
treatment with the phorbol ester, con¢rming results already
reported [7].
3.2. Tyrosine phosphorylation of TrkB
After electrophoresis of the immunoprecipitate obtained
from control cells, followed by Western blotting, the probing
with anti-TyrP antibodies showed the presence of a positive
band of about 145 kDa, corresponding to the mass of TrkB
(Fig. 2) [6]. The same analyses were performed on cells treated
with PMA and with PMA+BDNF. As a control also the
e¡ect of BDNF was checked. The membranes used for prob-
ing with anti-TyrP antibodies were submitted to stripping and
reprobed with anti-TrkB antibodies. The results showed that
the amount of TrkB in the immunoprecipitates was similar in
all the samples (Fig. 2). Tyrosine phosphorylation of each
sample was normalized for the TrkB content of the same
sample by calculating the ratio: intensity units of immuno-
reactivity to anti-TyrP/intensity units of immunoreactivity to
anti-TrkB, measured from the scanned images of the ECL
¢lms, as above described. The value of the normalized phos-
phorylation in control cells was 0.45 (arbitrary units). In the
following this value will be referred to as the basal phospho-
rylation level. Upon treatment with PMA, normalized tyro-
sine phosphorylation was strongly reduced to 0.32. When cells
were treated with PMA and BDNF, the value (0.29) was
comparable with the ¢gure obtained after PMA treatment
alone. On the contrary, and as expected, the phosphorylation
was strongly enhanced (2.3-fold with respect to the basal
phosphorylation level) upon cell treatment with BDNF.
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Fig. 1. Assessment of the amount of GM1 ganglioside in immuno-
precipitates obtained with anti-TrkB antibody from lysates of cere-
bellar granule cells. Total lipids were extracted from an aliquot of
the immunoprecipitates as described in the text. The extracts were
submitted to TLC, followed by immunostaining with HRP-conju-
gated cholera toxin B subunit and ECL detection. Lane 1: GM1
co-precipitated with TrkB from control cells ; lane 2: GM1 co-pre-
cipitated with TrkB from cells treated with 1 WM PMA for 7 min;
lane 3: GM1 co-precipitated with TrkB from cells treated with
PMA and 100 ng/ml BDNF for 7 min; St: 1 pmol standard GM1
ganglioside.
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4. Discussion
This investigation shows that the treatment of cerebellar
granule cells with PMA is followed by a remarkable change
both in the GM1 ganglioside amount associated with TrkB
and in the receptor activity, either basal or stimulated by
BDNF. To reach this conclusion, tyrosine phosphorylation
state of the receptor, and the content of GM1 ganglioside,
were assessed in immunoprecipitates obtained with anti-
TrkB antibodies from cells after di¡erent treatments. The
co-precipitation of GM1 ganglioside with TrkB was expected.
In fact, there have been reports of the occurrence of a tight
association between GM1 and Trk receptors [3]. Moreover,
recent data [5] show that TrkB is localized, along with other
Trk receptors, in those GM1-enriched domains of neuronal
plasma membranes which are involved in pivotal events such
as signal transduction. It is likely that the cell lysis carried out
by cold Triton X-100, a detergent widely used to isolate mem-
brane domains [12,13], does not completely disrupt the bilayer
assembly of granule cell plasma membrane, leaving detergent-
resistant TrkB-containing membrane rafts. Therefore, anti-
bodies directed against TrkB cause the receptor to precipitate
together with its glycolipid environment. The evaluation of
this possibility and that TrkB-GM1 interaction occurs within
specialized membrane domains is not the aim of the present
study, and deserves further investigation.
One of the di⁄culties to overcome, in investigating the role
of endogenous GM1 on TrkB activity, was how to change the
ganglioside density in the membrane region around the recep-
tor, without making use of exogenous glycolipid. For this
purpose, we employed short-term incubation with PMA, a
treatment we recently showed to induce a modi¢cation of
ganglioside exposure and segregation at the cell surface, as a
consequence of protein kinase C (PKC) activation [7,14]. This
approach gave the desired results (Fig. 1). In fact, upon PMA
treatment, the amount of GM1 ganglioside co-precipitated
with the receptor decreased with respect to control, untreated
cells, indicating a decrease of its local density around TrkB. It
can be argued that pretreatment with PMA could modify the
amount of GM1 in the plasma membrane. However, PMA
treatment did not a¡ect the total ganglioside content of the
cells, as shown by control experiments, and it is not reported
to a¡ect signi¢cantly the rate of £uid-phase endocytosis [7].
These data suggest that the treatment does not modify the
content of GM1 at the exoplasmic surface of the cell, and
strengthen the hypothesis that PMA elicits a redistribution
of ganglioside within the plasma membrane, displacing it
from the TrkB environment.
Most interestingly, the decrease was paralleled by a con-
comitant decrease of the tyrosine phosphorylation of TrkB.
Furthermore, under these circumstances, i.e. when the amount
of GM1 ganglioside associated with TrkB was lower, BDNF
was no longer able to stimulate the strong phosphorylation of
the receptor, normally exerted by this ligand (Fig. 2).
Is the e¡ect of PMA on TrkB activity mediated by PKC or
by the change in the ganglioside density near the receptor?
The mediation by PKC would be conceivable, because it is
known that its activation can a¡ect NT receptors. In fact, it
has been reported [15] that the proteolytic cleavage of the
extracellular domain of the NGF receptor, TrkA, is regulated
by PKC and by several receptor agonists (including NGF). As
a consequence of the cleavage, the amounts of TrkA and of its
phosphorylated form decrease. Although no similar e¡ect of
PKC on TrkB has been reported, a similar mechanism in our
system could not be excluded a priori. However, the amount
of immunoprecipitated TrkB protein in the di¡erent experi-
ments was nearly identical. This observation rules out the
occurrence of a PKC-stimulated cleavage of the receptor, at
least under the experimental conditions of short-term treat-
ment adopted here. Therefore, our data strongly suggest that
the observed PMA-induced decrease of TrkB tyrosine phos-
phorylation is not due to a proteolytic degradation of the
protein. Moreover, a kinase assay was carried out with radio-
active ATP, as described [3], on immunocomplexes obtained
from control and from PMA-treated cells. The analysis of the
autoradiogram showed a decrease of TrkB phosphorylation in
PMA-treated cells with respect to control, comparable to the
decrease of tyrosine phosphorylation detected with anti-TyrP
antibodies (data not shown). This result also rules out the
possibility of a phosphorylation of TrkB serine or threonine
residues exerted by PKC, and a possible consequent down-
regulation of receptor phosphorylation.
Summing up, these observations open the alternative stim-
ulating possibility that the decrease in the number of GM1
ganglioside molecules in the membrane area surrounding
TrkB, induced by PMA treatment, is responsible for the de-
crease in receptor activity, basal or stimulated by BDNF. It is
interesting to remember that an opposite change (increase) of
GM1 concentration in the plasma membrane, obtained by
addition of exogenous ganglioside, induces an increase in
Trk activity, and rescues neuronal cells from apoptotic death,
at least in part via Trk receptor dimerization and autophos-
phorylation [16]. Therefore, an appealing working hypothesis
is that a decrease of endogenous GM1 in the membrane area
surrounding TrkB prevents its dimerization, either basal or
stimulated by BDNF. Needless to say, the evaluation of this
hypothesis requires and deserves further experimental work.
Moreover, the observation that the change of ganglioside
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Fig. 2. Immunoblot analysis of TrkB with anti-phosphotyrosine and
with anti-TrkB antibodies. The immunoprecipitates obtained with
anti-TrkB from lysates of cerebellar granule cells were submitted to
SDS/8% polyacrylamide gel electrophoresis. Panel A: Western blot
analysis was performed with anti-phosphotyrosine antibody (4G10
from Upstate Biotechnology) and an ECL detection system. Panel
B: The same membranes were stripped and immunoblotted with
anti-TrkB (794, Santa Cruz) antibody. Lane 1: Control cells; lane
2: cells treated with 100 ng/ml BDNF for 7 min; lane 3: cells
treated with 1 WM PMA for 7 min; lane 4: cells treated with PMA
and 100 ng/ml BDNF for 7 min. The arrow indicates the molecular
weight (145 kDa) of TrkB.
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association with the receptor is consequent to PKC activation,
opens the possibility of a correlation between receptor mod-
ulation and trans-membrane signal transduction. It is also
worth noting that BDNF is able to evoke PKC activation
[17], thus also opening the possibility of a mechanism for
receptor down-regulation.
Considered overall, the present investigation indicates for
the ¢rst time that changes in the density of endogenous gly-
colipids in the environment of a receptor can modulate its
activity, and thus o¡ers intriguing new ideas towards an
understanding of biochemical phenomena involved in physio-
logical functions of the nervous system and in neurodegener-
ative disorders.
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